$EYPT
EyePoint Pharmaceuticals, Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513219166 Filed on May 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $492.0K $513.0K $538.0K
YoY Change -29.61% -4.65% 49.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.150M $1.740M $1.760M
YoY Change 34.38% -1.14% 0.0%
% of Gross Profit
Research & Development $2.320M $1.587M $1.508M
YoY Change 64.54% 5.24% -13.33%
% of Gross Profit
Depreciation & Amortization $250.0K $250.0K $230.0K
YoY Change -10.71% 8.7% -72.94%
% of Gross Profit
Operating Expenses $4.470M $3.325M $3.265M
YoY Change 48.5% 1.84% -6.71%
Operating Profit -$3.981M -$2.812M -$2.727M
YoY Change 72.34% 3.12% -13.13%
Interest Expense $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -97.06%
% of Operating Profit
Other Income/Expense, Net $0.00 $3.000K $11.00K
YoY Change -72.73%
Pretax Income -$3.980M -$2.809M -$2.716M
YoY Change 73.04% 3.42% -3.0%
Income Tax -$30.00K -$15.00K -$30.00K
% Of Pretax Income
Net Earnings -$3.947M -$2.794M -$2.686M
YoY Change 74.49% 4.02% 0.04%
Net Earnings / Revenue -802.24% -544.64% -499.26%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.695M -$1.197M -$1.293M
COMMON SHARES
Basic Shares Outstanding 23.30M shares 23.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.30M $13.70M $16.50M
YoY Change -29.45% -16.97% -28.57%
Cash & Equivalents $6.899M $7.998M $6.375M
Short-Term Investments $3.400M $5.700M $10.10M
Other Short-Term Assets $1.600M $500.0K $400.0K
YoY Change 300.0% 25.0% 0.0%
Inventory
Prepaid Expenses
Receivables $600.0K $1.000M $1.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.46M $15.21M $17.90M
YoY Change -21.9% -15.06% -26.34%
LONG-TERM ASSETS
Property, Plant & Equipment $179.0K $223.0K $400.0K
YoY Change -46.57% -44.25% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $100.0K $100.0K
YoY Change 100.0% 0.0% 0.0%
Total Long-Term Assets $3.785M $3.915M $4.900M
YoY Change -18.39% -20.1% -78.32%
TOTAL ASSETS
Total Short-Term Assets $12.46M $15.21M $17.90M
Total Long-Term Assets $3.785M $3.915M $4.900M
Total Assets $16.25M $19.12M $22.80M
YoY Change -21.11% -16.14% -51.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $671.0K $355.0K $300.0K
YoY Change 70.3% 18.33% 0.0%
Accrued Expenses $1.894M $1.437M $800.0K
YoY Change 211.51% 79.63% -11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.303M $2.685M $2.600M
YoY Change 3.93% 3.27% 73.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.200M $5.200M $4.700M
YoY Change 36.84% 10.64% -43.37%
Total Long-Term Liabilities $5.200M $5.200M $4.700M
YoY Change 36.84% 10.64% -43.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.303M $2.685M $2.600M
Total Long-Term Liabilities $5.200M $5.200M $4.700M
Total Liabilities $8.549M $7.879M $7.300M
YoY Change 22.81% 7.93% -26.26%
SHAREHOLDERS EQUITY
Retained Earnings -$263.7M -$259.7M
YoY Change 4.73%
Common Stock $23.00K $23.00K
YoY Change 9.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.700M $11.24M $15.60M
YoY Change
Total Liabilities & Shareholders Equity $16.25M $19.12M $22.80M
YoY Change -21.11% -16.14% -51.39%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$3.947M -$2.794M -$2.686M
YoY Change 74.49% 4.02% 0.04%
Depreciation, Depletion And Amortization $250.0K $250.0K $230.0K
YoY Change -10.71% 8.7% -72.94%
Cash From Operating Activities -$3.380M -$1.970M -$2.140M
YoY Change 83.7% -7.94% 32.1%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$10.00K -$20.00K
YoY Change 100.0% -50.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $2.300M $580.0K $120.0K
YoY Change 2200.0% 383.33% -104.72%
Cash From Investing Activities $2.280M $560.0K $110.0K
YoY Change 2433.33% 409.09% -104.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.380M -1.970M -2.140M
Cash From Investing Activities 2.280M 560.0K 110.0K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -1.100M -1.410M -2.030M
YoY Change -37.14% -30.54% -134.35%
FREE CASH FLOW
Cash From Operating Activities -$3.380M -$1.970M -$2.140M
Capital Expenditures -$20.00K -$10.00K -$20.00K
Free Cash Flow -$3.360M -$1.960M -$2.120M
YoY Change 83.61% -7.55% 31.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23297011 shares
CY2012Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.15
CY2012Q3 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
2.50
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6375000
CY2012Q1 psdv Unrecognized Tax Benefit
UnrecognizedTaxBenefit
CY2013Q1 us-gaap Other Assets
OtherAssets
73000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
914000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2685000
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
473000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
893000
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259711000
CY2013Q1 us-gaap Assets
Assets
19120000
CY2013Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13171000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7998000
CY2013Q1 us-gaap Deferred Revenue
DeferredRevenue
5600000
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19120000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23297011 shares
CY2013Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
11241000
CY2013Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3619000
CY2013Q1 us-gaap Available For Sale Securities Gross Unrealized Gain Loss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss
-5000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
355000
CY2013Q1 psdv Unrecognized Tax Benefit
UnrecognizedTaxBenefit
0
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
23000
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
5704000
CY2013Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1035000
CY2013Q1 us-gaap Liabilities
Liabilities
7879000
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1437000
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
223000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23297011 shares
CY2013Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5699000
CY2013Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5194000
CY2013Q1 us-gaap Assets Current
AssetsCurrent
15205000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
270015000
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 psdv Finite Lived Intangible Assets Remaining Useful Life
FiniteLivedIntangibleAssetsRemainingUsefulLife
4.75 Y
CY2013Q1 psdv Weighted Average Maturity
WeightedAverageMaturity
4.6 M
CY2013Q1 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
7472000
CY2013Q1 psdv Cash And Cash Equivalents And Marketable Securities Fair Value
CashAndCashEquivalentsAndMarketableSecuritiesFairValue
13700000
CY2013Q1 psdv Estimated Annual Amortization Of Intangible Assets
EstimatedAnnualAmortizationOfIntangibleAssets
760000
CY2013Q1 psdv Warrants Outstanding Weighted Average Remaining Contract Life
WarrantsOutstandingWeightedAverageRemainingContractLife
P3Y7M6D
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12912000
CY2012Q2 us-gaap Other Assets
OtherAssets
77000
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3178000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
421000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2176000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251758000
CY2012Q2 us-gaap Assets
Assets
20597000
CY2012Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14238000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4625000
CY2012Q2 us-gaap Deferred Revenue
DeferredRevenue
6000000
CY2012Q2 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
4292000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
394000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20802592 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
21000
CY2012Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
9954000
CY2012Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
967000
CY2012Q2 us-gaap Liabilities
Liabilities
6961000
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
608000
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
335000
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20802592 shares
CY2012Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9946000
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3783000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
15959000
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
264431000
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
13636000
CY2012Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4226000
CY2012Q2 us-gaap Available For Sale Securities Gross Unrealized Gain Loss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss
-8000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001314102
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Trading Symbol
TradingSymbol
PSDV
dei Entity Registrant Name
EntityRegistrantName
pSivida Corp.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4077000
us-gaap Investment Income Interest
InvestmentIncomeInterest
14000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
411760 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4685000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
138000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22960000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
918000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3373000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8050000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
785000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
918000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28000
us-gaap Net Income Loss
NetIncomeLoss
-7953000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5016000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4669000
us-gaap Royalty Revenue
RoyaltyRevenue
1048000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7981000
us-gaap Operating Expenses
OperatingExpenses
9701000
us-gaap Revenues
Revenues
1651000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
123000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
122000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-85000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-8000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
603000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4668000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
578000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3000
us-gaap Depreciation
Depreciation
168000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7758000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
918000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8038000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4846220 shares
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11884000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4669000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5365000
psdv Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
10 years
psdv Milestone Payment Due Upon Approval By Fda
MilestonePaymentDueUponApprovalByFda
25000000
psdv Noncash Or Part Noncash Unpaid Property Plant Equipment And Other Assets
NoncashOrPartNoncashUnpaidPropertyPlantEquipmentAndOtherAssets
14000
psdv Number Of Options Vested During Period
NumberOfOptionsVestedDuringPeriod
645826 shares
psdv Number Of Patient Under Trial
NumberOfPatientUnderTrial
300 Patient
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
114000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
515000
us-gaap Investment Income Interest
InvestmentIncomeInterest
30000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5629000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1700000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-449000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20787000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
1021000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6537000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1103000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22901000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-525000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14830000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-440000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-13000
us-gaap Net Income Loss
NetIncomeLoss
-22573000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
199000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5269000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114000
us-gaap Royalty Revenue
RoyaltyRevenue
1004000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23013000
us-gaap Operating Expenses
OperatingExpenses
25728000
us-gaap Revenues
Revenues
2827000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
223000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
212000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-129000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
170000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
1823000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
399000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1844000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
9000
us-gaap Depreciation
Depreciation
112000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12238000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1021000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22702000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8171381 shares
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12049000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7163000
CY2012Q3 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
694000
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2494419 shares
CY2012Q3 psdv Term Of Warrants Issued
TermOfWarrantsIssued
5 Y
CY2012Q3 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
623605 shares
CY2012Q3 psdv Percentage Of Shares Of Common Stock Issued Under Terms Of Warrant Transactions
PercentageOfSharesOfCommonStockIssuedUnderTermsOfWarrantTransactions
0.25 pure
CY2012Q3 psdv Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5400000
CY2012Q3 psdv Warrants Exercisable Date
WarrantsExercisableDate
2013-03-31
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1587000
CY2013Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-87000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23297000 shares
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2812000
CY2013Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-87000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-2794000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1738000
CY2013Q1 us-gaap Royalty Revenue
RoyaltyRevenue
274000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2881000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
3325000
CY2013Q1 us-gaap Revenues
Revenues
513000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-15000
CY2013Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
239000
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
192000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
312000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2809000
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1508000
CY2012Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
65000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20803000 shares
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2727000
CY2012Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
69000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-2686000
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1757000
CY2012Q1 us-gaap Royalty Revenue
RoyaltyRevenue
380000
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2617000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
3265000
CY2012Q1 us-gaap Revenues
Revenues
538000
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-30000
CY2012Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
158000
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
192000
CY2012Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
4000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
379000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2716000
CY2011Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14830000

Files In Submission

Name View Source Status
0001193125-13-219166-index-headers.html Edgar Link pending
0001193125-13-219166-index.html Edgar Link pending
0001193125-13-219166.txt Edgar Link pending
0001193125-13-219166-xbrl.zip Edgar Link pending
d513053d10q.htm Edgar Link pending
d513053dex311.htm Edgar Link pending
d513053dex312.htm Edgar Link pending
d513053dex321.htm Edgar Link pending
d513053dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
psdv-20130331.xml Edgar Link completed
psdv-20130331.xsd Edgar Link pending
psdv-20130331_cal.xml Edgar Link unprocessable
psdv-20130331_def.xml Edgar Link unprocessable
psdv-20130331_lab.xml Edgar Link unprocessable
psdv-20130331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending